Merck Halts Acquisition Talks with Cancer Biotech Firm "Revolution Medicines"
No Agreement Reached on Acquisition Price Between the Two Companies
RevMed to Release Key Clinical Trial Data This Year
It has been reported that Merck, the U.S. pharmaceutical company, has halted acquisition talks with Revolution Medicines (hereafter referred to as RevMed), a developer of new cancer drugs.
On January 25 (local time), The Wall Street Journal (WSJ) reported, citing sources familiar with the matter, that negotiations between Merck and RevMed broke down as the two parties failed to reach an agreement on the acquisition price.
Merck had initially been in talks to acquire RevMed recently. If the deal had gone through, the company’s valuation could have reached around 30 billion dollars (approximately 43 trillion won). However, sources stated that the negotiations collapsed as both sides could not agree on the acquisition price.
They added, however, that it is still possible for negotiations to resume in the future or for other potential acquirers interested in RevMed to emerge. RevMed is scheduled to release key clinical trial data for its pancreatic and colorectal cancer drug candidates in the first half of this year.
RevMed is developing new drugs targeting the RAS protein, which is known as a molecular cause of cancer. The company’s experimental therapies block this molecular pathway. Their aim is to suppress major cancers that have been difficult to treat, such as lung cancer, pancreatic cancer, and colorectal cancer.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
RevMed’s drug candidates are regarded as showing potential to overcome these challenges. Mizuho Securities has projected that if the pancreatic cancer drug candidate proves its safety and efficacy, RevMed could effectively dominate this treatment field and generate global sales of 10 billion dollars (about 14 trillion won) by 2035.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.